

Only the mediocre are always at their best

Seuls les médiocres sont toujours à leur meilleur

Jean Giraudoux

Are we at our best?



>\$250B a year invested in biomedical research

 For many diseases, we still don't even understand molecular mechanisms, let alone how to design a therapeutic strategy

• Medicines are not affordable for most people in the world

Redundancy is one cause





SGC – focusing on the "ignored"



- Founded 2003, an "open science" consortium to help understand human biology and find new drug targets
 - Major focus is to generate high-quality research tools (evidencebased decision)
 - Main focus is on the lesser studied proteins
 - To minimize waste, we share freely and never patent, as a core principle
- Top-down, organized university-based laboratories in 6 countries, ~300 scientists
- Laser focus on high quality science
 - 2.5 papers per week, >300 in journals with impact factor >10
 - 13% of all human protein structure information in public domain
 - Leading reputation for reproducibility (electronic lab books since 2005)

Our aim by 2030



- Have developed a freely available molecular modulator(s) for every human protein, to enable fundamental discoveries.
 - Tools to seed discoveries
- Create large sharing network that includes clinicians and patients as partners in fundamental science and drug discovery
 - Humans are the only relevant experimental model
- From our scientific insights, create large numbers of open drug discovery companies to advance drugs to regulatory approval, with the primary objective of <u>affordability</u>.
 - We need to re-brand "innovative drug discovery" as "experimental medicine"
- We can only do all this if align and gain trust of all people we need to be the most aggressive open science organization in world
 - We need to be *uncomfortably* open

Open science is key to success

SGC

Open science

- more efficient way to innovate
- reduces redundancy
- improves reproducibility
- more fun

"Open science is not the aim, but the solution"

Open science impact



- Open chemical probes
- Open hospital network
- Open lab notebook (Rachel)
- Open academic institutions
- Open chemogenomic libraries
- Open drug discovery

- 13% of world's human protein structures
- >10,000 samples sent, referenced in 3,000 papers
- New indication for drug; new commitments of \$5M
- >7,500 visitors; 15 new collaborations
 - Two new investment by pharma in basic science (\$3M)
 - 9 companies have donated >1,000 advanced compounds
 - Company formed CEO identified \$3M raised



The lab note book situation

- SGC
- Avg. time between experiment and wide public disclosure is years
- There are a million biomedical researchers
- The system effectively condones 1-2 million years of scientific delay, each year
 - How many roads were not taken?
 - How many redundant experiments were performed?
- Is there any rational reason not to share?
- Why does the public fund science? To make our CV's better?

My lab note book aims

- SGC
- Accelerate discoveries by sharing freely and quickly
- Create a broader culture of sharing
- Elicit scientific input into our experiments
- Reduce wasteful experiments
- Increase stakeholder engagement in science
- Increase reproducibility have record of negative data

My lab note book concerns



- How do we measure success?
- How do we reward success?
- How do we make the notebooks searchable?
- How does one reference someone's lab notes?

How funders might help



- Create metrics (downloads?) that reward data/notebook generators
- Insist funded scientists use electronic lab notebooks